baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Call 48 BMY 16.01.2.../ DE000SW9CVR8 /

2024-05-16 9:38:11 PM	Chg.-0.020	Bid9:58:04 PM	Ask9:58:04 PM	Underlying	Strike price	Expiration date	Option type
0.440EUR	-4.35%	0.440 Bid Size: 20,000	0.450 Ask Size: 20,000	Bristol Myers Squibb...	48.00 USD	2026-01-16	Call

GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 05-15 Lantheus Announces Executive Appointments to Accelerate Innovation

GlobeNewswire 05-14 Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...

GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 05-13 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05-08 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Immunocore reports first quarter financial results and provides a business update

GlobeNewswire 05-07 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...

GlobeNewswire 05-02 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...

GlobeNewswire 05-01 Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

GlobeNewswire 05-01 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...

GlobeNewswire 04-30 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

GlobeNewswire 04-30 CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical D...

GlobeNewswire 04-25 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...

GlobeNewswire 04-25 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...

GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 04-22 ArriVent Appoints Kristine Peterson to its Board of Directors

GlobeNewswire 04-08 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...

GlobeNewswire 04-08 Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

GlobeNewswire 04-08 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H.,...

GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 04-05 Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies D...

GlobeNewswire 04-03 Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the...

GlobeNewswire 04-03 CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...

GlobeNewswire 04-02 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered ...

Soc. Generale Call 48 BMY 16.01.2.../ DE000SW9CVR8 /

If you wish to receive reply to your feedback, please provide your email address.